Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
about
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancerPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaPI3K inhibitors as new cancer therapeutics: implications for clinical trial designSequence of treatment in locally advanced and metastatic renal cell carcinomaTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNAKilling me softly--future challenges in apoptosis researchHeterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agentsmiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.Differential network analysis from cross-platform gene expression data.Identifying differential networks based on multi-platform gene expression data.The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene.Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and preventionCytoplasmic localization of p21 protects trophoblast giant cells from DNA damage induced apoptosis.Estradiol Suppresses TLR4-triggered Apoptosis of Decidual Stromal Cells and Drives an Anti-inflammatory TH2 Shift by Activating SGK1.Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signalingClinical significance of aberrant mammalian target of rapamycin expression in stage IIIB colon cancer.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Role of AKT signaling in DNA repair and clinical response to cancer therapy.Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancersExperimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibodyRTK/ERK pathway under natural selection associated with prostate cancer.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerComputational systems biology approaches to anti-angiogenic cancer therapeutics.New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.The Rapalogue, CCI-779, improves salivary gland function following radiation.Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.Immunomodulatory Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells.Toward a Cancer Drug of Fungal OriginStimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
P2860
Q24185960-B8E70CC9-6816-4A01-A14B-57D497D90E9FQ26766293-2C2EE056-658F-490B-8DE7-D53CB0093593Q26770489-D8B2989D-4090-4586-9E12-908B64631176Q26773653-68B5316C-7D6D-4E22-AC9B-4A098DCBD0BCQ26775940-1B9BC021-804F-498D-BB08-74CF2E5C8869Q27011221-C49FFAB7-4778-4D13-9499-19579EEEAD64Q27025213-FE7A6BB1-3611-4031-9C05-37D0463A22F2Q27853391-E78DA4E5-5310-4759-A2EC-D6D3E43119DCQ28067417-15960904-E3A7-4F3E-8346-6DCD7CF6D8A3Q28606716-18AD7701-383E-4982-B0EC-685AD640A98CQ30412086-4F3E6BEA-49C8-4ED8-8C7A-83B02A1AFF28Q31106994-500C9C2F-FE7A-48D9-BF31-41440BC1B25EQ31133441-56A952A4-80B9-408D-B8FC-FF9E2A442F9DQ31143551-B4C690D4-ACD8-44EF-A067-20BA5A71328BQ31157634-A00448BF-8667-4D9D-9185-C39DB3A3C66CQ33433009-F49B37C7-DA0B-47CF-B2DE-E78FC79709E1Q33618824-9918EF39-9E5E-47AC-A027-D76DB2807FB2Q33642284-A1BD8973-A33E-4510-8E62-4AA13B79E7DBQ33644593-9E59398D-6F5C-490D-8E40-603FFBFD477BQ33703276-8E7E8CCE-B1B6-401D-B92C-122739779B6CQ33838622-1D6C96FF-A912-4B7F-9D2D-7552B6943221Q33858387-DC97FE6D-73B3-4ECA-937C-747967112646Q33903949-1A873CEB-87F6-4338-AF7B-1141B9DE08E6Q33968034-A1722D0B-B3A5-467E-B85C-DC4E9E5C5154Q34022694-F14F74DC-C65D-437B-9672-B9CD7520FB75Q34147910-893DD4C9-FAA4-47E2-BA8E-4CAE36F284ADQ34193741-4CB89854-DAD4-4B7B-BDE2-5BFBE6EE76E2Q34200109-60DD5EF8-BE18-4E9D-89E5-CDB4C0CD85AEQ34677991-306F15D7-A50C-4D7F-B364-191CA78433E8Q35040853-8B986E17-2520-41A7-895E-28A797055302Q35070321-936621E0-E39B-401A-8695-2BF2AA0F9C84Q35072441-B8613DA6-5673-4756-83AC-B5C71A35B885Q35108084-6A9C0DE9-7C10-436A-83CB-17FEDF0C1DF4Q35168124-255602C2-F774-452A-B4E8-23DB71826083Q35463371-F07D7C17-F47C-4552-A416-694F039B25BDQ35505109-8DF49F12-E854-4FDA-ACC8-ED6CE7C42911Q35577645-74A7FBF2-6AB1-4C73-8BF1-A2B70ABBDAD6Q35596957-3A614311-903B-476D-A82E-D544DB7D0DB7Q35610049-BF9CC593-3B25-4300-AF78-E0E5812EECA5Q35677134-414BBCCF-CA5C-4C27-90E0-E8A0FAE97DF7
P2860
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
@en
type
label
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
@en
prefLabel
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
@en
P1476
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
@en
P2093
Howard A Burris
P2888
P304
P356
10.1007/S00280-012-2043-3
P577
2013-02-03T00:00:00Z
P6179
1028670617